Today, in Sacramento, California, Lunai Bioworks (NASDAQ: LNAI), a biotechnology company utilizing AI to develop precision therapeutics, revealed the discovery of three significant subtypes of Parkinson's disease. They have also prioritized drug targets that show promise for treatment.